Skip to main content

BioSyent Inc. (BIOYF)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
66.0Fair

ValueMarkers Composite Index

Top 96%#1,815 of 44,707
Undervalued

30% below intrinsic value ($11)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-1.95
Investigate
Altman
12.54
Safe
DCF Value
$11
Undervalued
ROIC
20.1%
Strong
P/E
18.7
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

BioSyent Inc. (BIOYF) — VMCI valuation read

The headline on BioSyent Inc. (BIOYF) is a 66/100 VMCI score, set against a Healthcare sector median of 50. That 16-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

BIOYF insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** BIOYF trades at 17.0x earnings, 6% below the Healthcare median of 18.0x sets the value side. ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -1.2x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on BIOYF.

BIOYF rose 1.3% over the trailing 7 days, with a -22.5% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in BIOYF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.